Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Vitamin D therapy improves female sexual function

03 Dec 2018

Women with deficient vitamin D levels and sexual dysfunction may benefit from vitamin D supplementation, which has been shown to yield improvements in sexual function.

In a recent study, 76 women aged 18-45 years with sexual dysfunction (Female Sexual Functioning Index [FSFI] score <26.55) and a serum 25-hydroxyvitamin D (25(OH)D) level of <30 ng/mL were randomized to receive an intramuscular injection of 300,000 IU cholecalciferol (n=38) or a placebo (n=38). Treatment was administered at baseline and after 4 weeks.

FSFI was evaluated at baseline and then after 4 and 8 weeks, whereas serum 25(OH)D levels and depression symptoms (Beck Depression Inventory) were evaluated at baseline and at 8 weeks.

At week 8, serum levels of 25(OH)D increased by a mean of 14.4 ng/mL in the cholecalciferol group (p<0.001) but not in the placebo group.

Moreover, compared with placebo, cholecalciferol supplementation led to a significant increase in the FSFI score at weeks 4 (19.6 vs 16.3; p=0.002) and 8 (25.0 vs 17.1; p<0.001).

The Beck Depression Inventory score decreased by –21.0 in the cholecalciferol group (p<0.001), while no changes occurred in the placebo group.

Of note, the effect of treatment on sexual function was independent from the observed effect on symptoms of depression.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.